科伦药业：博度曲妥珠单抗治疗2L+ HER2+乳腺癌获批准上市

Core Viewpoint - The company, Kelun Pharmaceutical, announced that its subsidiary, Sichuan Kelun Botai Biopharmaceutical Co., Ltd., received approval from the National Medical Products Administration (NMPA) for its antibody-drug conjugate (ADC) A166 (also known as Trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received one or more anti-HER2 therapies [1] Group 1 - The ADC A166 targets the human epidermal growth factor receptor 2 (HER2) [1] - The approval is specifically for patients with unresectable or metastatic HER2-positive breast cancer [1] - The indication is for those who have previously undergone treatment with one or more anti-HER2 drugs [1]